Description
The fixed-dose combination of ledipasvir-sofosbuvir and provides an effective and well-tolerated one-pill once-a-day option for treatment of genotypes 1, 4, 5, and 6 chronic hepatitis C (HCV) infection.
-
- This direct-acting antiviral regimen was the first FDA-approved interferon- and ribavirin-free regimen to treat hepatitis C.
-
- Ledipasvir-sofosbuvir can be used without ribavirin in most patients with genotype 1A, except those who are cirrhotic and treatment-experienced.
-
- In addition, persons with HCV genotype 1 may be eligible for an 8-week duration if they are treatment-naïve, without cirrhosis, and have a pretreatment HCV RNA level less than 6 million. Similar to sofosbuvir-velpatasvir, the other NS5B-NS5A inhibitor combination, ledipasvir-sofosbuvir is safe and effective for the treatment of HCV in persons with decompensated cirrhosis.
How to use:
-
- Ledipasvir-sofosbuvir (90 mg/400 mg) is a fixed-dose combination tablet.
-
- The recommended dosage is one tablet once daily, with or without food.
Caution & Warnings:
-
- Risk of HBV reactivation in patients coinfected with HCV and HBV.
Side Effects:
-
- Fatigue and headache.
Ingredients:
- Ledipasvir, sofosbuvir 90mg/400mg.
Reviews
There are no reviews yet.